<DOC>
	<DOCNO>NCT01990846</DOCNO>
	<brief_summary>To evaluate safety , tolerability pharmacokinetics ( PK ) single , repeat escalate dos FF-3 dry powder administer via inhalation healthy adult subject</brief_summary>
	<brief_title>Safety , Tolerability , PK Escalating Doses Flufirvitide-3 Dry Powder Inhalation Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male nonpregnant , nonlactating female subject 18 50 year age inclusive . 2 . Body Mass Index ( BMI ) 18 30 kg/m2 inclusive body weight 50 100 kg inclusive . 3 . Normal spirometry value Screening Baseline define force vital capacity ( FVC ) force expiratory volume one second ( FEV1 ) great 80 % predict LLN FEV1/FVC ratio great 70 % . Results FEV1 FVC must reproducible ( ± 5 % ) Screening Baseline . 4 . Postmenopausal woman amenorrhea least 2 year eligible ( confirmed follicle stimulate hormone [ FSH ] test ) . 5 . Females childbearing potential must use acceptable birth control method throughout study 30 day last dose IMP : 6 . Male subject : 1 . Must agree use condom ( diaphragm plus spermicide female partner ) time first dose IMP 90 day last dose . 2 . Must agree donate sperm 90 day last dose IMP . 3 . Vasectomies males 6 month minimum prior first dose IMP acceptable form contraception . 4 . Males claim abstinence method contraception allow provided agree use barrier method ( diaphragm plus spermicide female partner condom ) become sexually active screen 90 day last dose IMP . 7 . Willing able provide write informed consent provide authorization use protect health information ( HIPAA ) . 8 . Willing able adhere lifestyle guideline restriction outline protocol . 9 . Willing able confine CRU require protocol . Exclusion Criteria 1 . Evidence history clinically significant oncologic , pulmonary , hepatic , gastrointestinal , cardiovascular , hematologic , metabolic , neurological , immunologic , nephrologic , endocrine , psychiatric disease , current clinically significant infection . 2 . History and/or presence asthma Screening Baseline ; presence active rhinitis sinusitis Screening Baseline . 3 . Clinically significant nasal abnormality include nasal septum deviation , septum perforation , polyp , history recurrent epistaxis , history sinus surgery and/or persistent hypertrophic inferior turbinate . 4 . Clinically significant abnormality Screening Baseline safety laboratory test , ECGs , spirometry . 5 . Inability perform spirometry accord 2005 American Thoracic Society ( ATS ) acceptability repeatability standard . 6 . History significant nasal irritation use nasal spray drop . 7 . Corrected QT interval ( QTc ) great 450 msec male 470 msec female correct Fridericia formula . 8 . History drug alcohol abuse within past 2 year ; current excessive user alcohol define regular weekly intake great 15 unit male subject 10 unit female subject . One unit equal 25 mL spirit , 125 mL wine 250 mL beer . 9 . Tobacco user ( include user stop smoke £90 day prior screen evaluation ) . [ Note : `` Tobacco use '' include smoking use snuff chew tobacco , nicotine nicotine containing product . ] 10 . Received IMP participate another research study within 30 day first dose IMP study . 11 . Participated previous investigational study FF3 . 12 . History influenza vaccination live vaccine within 7 day attenuate vaccine within 14 day first dose IMP . 13 . Use prescription drug within 14 day prior first dose IMP , except oral contraceptive . 14 . Received nonprescription medication , vitamin , dietary supplement within 7 day administration first dose IMP , unless prior approval grant Principal Investigator Medical Monitor . Excluded list intermittent use acetaminophen £2 g/day ibuprofen £1200 mg/day . Herbal supplement must discontinue 14 day prior first dose IMP . 15 . Use antihistamine and/or decongestant within 30 day nasal corticosteroid within 3 month prior first dose IMP . 16 . Consumed alcohol within 72 hour Day 1 positive alcohol test Screening admission CRU . 17 . Subjects consume grapefruit juice juice contain grapefruit ate grapefruit ate Seville oranges within 7 day prior first dose IMP . 18 . Excessive intake caffeinecontaining food beverage ( 5 unit equivalent per day ) within 48 hour prior admission study center ( Day 1 ) . One caffeine unit contain follow item : 1 ( 6 oz ) cup coffee , 2 ( 12 oz ) can cola , 1 ( 12 oz ) glass tea , ½ ( 4 oz ) cup energy drink ( e.g. , Red Bull ) 3 ( 1 oz ) chocolate bar . 19 . Positive serum pregnancy test Screening Visit positive urine pregnancy test Day 1 ( female ) . 20 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) antihepatitis C virus ( antiHCV ) Screening Visit . 21 . Positive urine drug test Screening Visit admission CRU . 22 . Likelihood require treatment study period drug permit study protocol . 23 . Subjects donate blood experienced significant blood loss within 56 day screen study . 24 . Subjects hemoglobin ( Hb ) &lt; 11 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>antiviral , influenza</keyword>
</DOC>